NCT06333496Completed
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
Effect of a Glucagon Like Peptide 1 (GLP1) Booster on Blood Glucose, HbA1c, Insulin, and GLP1 Levels, Body Weight and Body Fat in Overweight Adult Men and Women
Source: ClinicalTrials.gov · Last updated 5 Dec 2024
Brief summary (registry, in English)
BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight. PURPOSE The purpose of this study is to assess several clinical endpoints and questionnaires in healthy volunteers taking the new GB formula. SCOPE The scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. In brief, the non-clinical design will be an open-label study involving volunteers taking GB everyday for 12 weeks. Data analysis will involve measuring the clinical endpoints across the group at different timepoints.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 12 (actual)
- First submitted
- 11 Mar 2024
- Start date
- 2 Jan 2024
- Primary completion date
- 29 Mar 2024
- Lead sponsor
- Alpine Biotech LLC
- Diseases
- Obesity
- NCT number
- NCT06333496
What you commit to
- Study type: Interventional
- Participants enrolled: 12
- From 2 Jan 2024 to the primary completion date, 29 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Volunteers who are taking any stimulant medications (e.g. Adderall, Adzenys, Dexedrine, Ritalin, Methylphenidate, etc).
Other
- Female volunteers who are pregnant or planning to become pregnant within the next three months.
Who the study is looking for
- Volunteers must be over the age of 18.
- Volunteers cannot be smokers.
- Volunteers cannot be currently taking a dietary supplement or prescription for weight loss.
- Exercising volunteers must maintain their regimen consistently throughout the course of the 12-week study.
- Caffeine drinking volunteers must maintain their caffeine intake consistently throughout the course of the 12-week study.
- Volunteers need to be overweight but not obese, as defined by having a BMI between 25.0 and 29.9
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Alpine Bio Coordinator of this site? Confirm its status | Salt Lake City | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.